Sandbox/AL: Difference between revisions

Revision as of 13:43, 7 July 2014

Fondaparinux
Arixtra^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Fondaparinux
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2] For patient information, click here. Synonyms / Brand Names: Arixtra^®

Overview

Fondaparinux (trade name Arixtra) is an anticoagulant medication chemically related to low molecular weight heparins. It is marketed by GlaxoSmithKline. A generic version developed by Alchemia is marketed within the US by Dr. Reddy's Laboratories.

FDA Package Insert

Arixtra^®

Mechanism of Action

The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development.

Fondaparinux sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, fondaparinux sodium does not affectfibrinolytic activity or bleeding time.^[1]

References

↑ "ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC]".

[dailymed.nlm.nih.gov-1] "ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC]".

[1]

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{Dobutamine}}
+{{Fondaparinux}}
 {{CMG}}; {{AE}} {{AZ}}
+'''''For patient information, click <u>[[Fondaparinux (patient information)|here]]'''''</u>.
-'''''For patient information about Dobutamine, click [[Dobutamine (patient information)|here]]'''''.
+{{SB}} Arixtra<sup>®</sup>
-{{SB}}
 ==Overview==
+'''Fondaparinux''' (trade name '''Arixtra''') is an [[anticoagulant]] medication chemically related to [[low molecular weight heparin]]s. It is marketed by [[GlaxoSmithKline]]. A generic version developed by Alchemia is marketed within the US by [[Dr. Reddy's Laboratories]].
 ==Category==
+[[Factor Xa]] inhibitors.
 ==FDA Package Insert==
+===Arixtra<sup>®</sup>===
+'''| [[Fondaparinux indications and usage|Indications and Usage]]'''
+'''| [[Fondaparinux dosage and administration|Dosage and Administration]]'''
+'''| [[Fondaparinux dosage forms and strengths|Dosage Forms and Strengths]]'''
+'''| [[Fondaparinux contraindications|Contraindications]]'''
+'''| [[Fondaparinux warnings|Warnings and Precautions]]'''
+'''| [[Fondaparinux adverse reactions|Adverse Reactions]]'''
+'''| [[Fondaparinux drug interactions|Drug Interactions]]'''
+'''| [[Fondaparinux use in specific populations|Use in Specific Populations]]'''
+'''| [[Fondaparinux overdosage|Overdosage]]'''
+'''| [[Fondaparinux description|Description]]'''
+'''| [[Fondaparinux clinical pharmacology|Clinical Pharmacology]]'''
+'''| [[Fondaparinux nonclinical toxicology|Nonclinical Toxicology]]'''
+'''| [[Fondaparinux clinical studies|Clinical Studies]]'''
+'''| [[Fondaparinux how supplied storage and handling|How Supplied/Storage and Handling]]'''
+'''| [[Fondaparinux patient counseling information|Patient Counseling Information]]'''
+'''| [[Fondaparinux labels and packages|Labels and Packages]]'''
-'''| [[Dobutamine indications and usage|Indications and Usage]]'''
+[[image:fond.png]]
-'''| [[Dobutamine dosage and administration|Dosage and Administration]]'''
-'''| [[Dobutamine dosage forms and strengths|Dosage Forms and Strengths]]'''
-'''| [[Dobutamine contraindications|Contraindications]]'''
-'''| [[Dobutamine warnings|Warnings and Precautions]]'''
-'''| [[Dobutamine adverse reactions|Adverse Reactions]]'''
-'''| [[Dobutamine drug interactions|Drug Interactions]]'''
-'''| [[Dobutamine use in specific populations|Use in Specific Populations]]'''
-'''| [[Dobutamine overdosage|Overdosage]]'''
-'''| [[Dobutamine description|Description]]'''
-'''| [[Dobutamine clinical pharmacology|Clinical Pharmacology]]'''
-'''| [[Dobutamine nonclinical toxicology|Nonclinical Toxicology]]'''
-'''| [[Dobutamine clinical studies|Clinical Studies]]'''
-'''| [[Dobutamine how supplied storage and handling|How Supplied/Storage and Handling]]'''
-'''| [[Dobutamine patient counseling information|Patient Counseling Information]]'''
-'''| [[Dobutamine labels and packages|Labels and Packages]]'''
 ==Mechanism of Action==
+The antithrombotic activity of fondaparinux sodium is the result of [[antithrombin]] III (ATIII)-mediated selective inhibition of [[Factor Xa]]. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits [[thrombin ]]formation and thrombus development.
+Fondaparinux sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, fondaparinux sodium does not affect[[ fibrinolytic ]]activity or bleeding time.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher =  | date =  | accessdate = }}</ref>
 ==References==
 {{Reflist|2}}
+[[Category:Cardiovascular Drugs]]
 [[Category:Drugs]]